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Background: Mutations in the KIF21A gene are detected in the patients with congenital fibrosis of the extraocular
muscles. Mutations in the PAX6 gene are detected in the patients with congenital aniridia.
Case presentation: Herein we report a boy with both congenital fibrosis of extraocular muscles and aniridia.
Sequence analysis of his KIF21A and PAX6 genes reveals a 1-bp deletion (c.745delC) in the PAX6 gene and a
missense mutation of c.2860C > T (p.Arg954Trp) in KIF21A.
Conclusions: This study demonstrates that the occurrence of independent mutations in more than a single gene
in a patient may lead to a complex phenotype.Background
Congenital fibrosis of the extraocular muscles (CFEOM) is
a clinically and genetically heterogeneous group of ocular
motor diseases characterized by congenital restrictive
ophthalmoplegia affecting extraocular muscles innervated
by the oculomotor and/or trochlear nerves [1]. Three types
of CFEOM have been defined according to the inheritance
pattern and clinical features. CFEOM1 (OMIM,135700)
is an autosomal dominant disorder with complete pene-
trance and caused by the mutations in the KIF21A gene
(OMIM,608283) on chromosome 12q12. Individuals
with CFEOM1 have typical clinical phenotypes including
bilateral blepharoptosis, chin elevation and downward fix-
ation of both eyes without ability to elevate above the hori-
zontal midline. CFEOM2 (OMIM,602078) is an autosomal
recessive disorder caused by mutations in the ARIX gene
(OMIM, 602753) on chromosome 11q13. The affected
individual shows bilateral ptosis and ophthalmoplegia with
the globes “frozen” in an extreme abducted position.
CFEOM3 is an autosomal dominant disorder with in-
complete penetrance and shows variable clinical features.
Affected individuals may have unilateral or bilateral re-
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reproduction in any medium, provided the orand can raise their eyes above midline. CFEOM3 has
been further sub-categorized into CFEOM3A, CFEOM3B
and CFEOM3C. CFEOM3A (OMIM, 600638) is caused
by mutations in the TUBB3 gene (OMIM, 602661) on
chromosome 16q24, and CFEOM3B (OMIM, 608283)
is caused by mutations in the KIF21A gene. CFEOM3C
(OMIM,609384) has been mapped to chromosome 13q.
Congenital aniridia (OMIM,106210) is a rare ocular
malformation that affects the development of multiple
ocular structures. The most noticeable sign of this disorder
is complete or partial iris hypoplasia with associated foveal
hypoplasia, resulting in reduced visual acuity and nystag-
mus presenting in early infancy. Other ocular anomalies,
such as corneal opacity, cataract, glaucoma, coloboma and
optic nerve hypoplasia, are also frequently associated with
aniridia [2]. Aniridia may occur either as an isolated ocular
abnormality without systemic involvement, caused by
mutations in the Paired Box gene 6 (PAX6) located on
chromosome 11p13, or as a part of the Wilms tumor-
aniridia-genital anomalies-retardation (WAGR) syndrome
(OMIM,194072), caused by deletion of a region of chromo-
some 11p13-p12 containing both the Wilms tumor 1
(WT1) and PAX6 genes. In addition, PAX6 gene mutations
can be associated with brain malformations [3].
Here we report a male proband with aniridia and
CFEOM1. He was determined to have inherited a KIF21A
gene mutation from his mother who is the daughter andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proband inherited a mutation in PAX6 from his father,
who also had congenital aniridia.
Case presentation
A 7-year old male (individual III:1, Figure 1A) with both
CFEOM1 and congenital aniridia was recruited as
were his family members, including his parents, grand-
father (individual I:1), grandmother (individual I:2), uncle
(individual II:3) and aunt (individual II:4). He was found
to have no ability to make pursuit movements soon after
birth. Ophthalmologic examinations at age 2 revealed
that he had congenital fibrosis of the extraocular muscles,
aniridia, foveal hypoplasia, and nystagmus, but had normal
corneas and transparent lenses.
His grandfather (individual I:1) was the first individual
in this pedigree to have congenital fibrosis of extraocular
muscles. The grandfather was found to have limited
extraocular movement soon after birth and underwent
strabismus surgery for treatment of CFEOM in 1991. His
head posture and ocular movement had been improved
after surgery. The boy’s mother underwent strabismus
surgery for CFEOM treatment in 2003. Her head pos-
ture and eye position were improved after surgery. His
uncle (individual II:3) was diagnosed with CFEOM, but
has not undergone strabismus surgery. All affected in-
dividuals with CFEOM in this family have typical fea-
tures of CFEOM1 including bilateral blepharoptosis,
chin elevation and ophthalmoplegia with the eyes fixed
in an infraducted position of roughly 20 to 30 degrees










Figure 1 Phenotypes of the affected boy and his parents. (A)
The pedigree, showing the boy inheriting CFEOM from his mother
and aniridia from his father. (B) The boy and his mother, both of
them with typical clinical features of CFEOM1. (C) The photo of the
anterior segment in the left eye of the boy’s father, showing aniridia.
(D) Aniridia in the left eye of the boy.The proband’s father was affected with congenital
aniridia, foveal hypoplasia and nystagmus. The iris was
completely absent at its base in both of his eyes, similar
to the iris in the boy’s eyes (Figure 1C, 1D). He had normal
corneas and transparent lenses with the best corrected vis-
ual acuity of 0.1 in both of his eyes. In addition to an ocular
examination, systemic and neurological examinations were
also performed for all affected individuals in this family. For
differentiating isolated aniridia from WAGR syndrome,
abdominal ultrasonographic assessments were performed
in each of the affected individuals with aniridia. However,
no abnormal signs in the kidney or urogenital system were
detected by B-scan, and neither were mental retardation,
cerebellar anomaly, and olfactory or hearing difficulties
found in the boy and his father as well.
Method
Mutation analysis
This study was approved by the Ethics Committee of
Tianjin Eye Hospital and was conducted in accordance
with the Declaration of Helsinki. After the written informed
consent was obtained from all participants, 3 ml blood
samples were taken from each individual and DNA was
extracted from blood lymphocytes, according to the
standard methods of protocol (Roche Biochemical, Inc).
The sequence analysis of PAX6 and KIF21A genes was
performed by direct DNA sequencing. All coding re-
gions of the PAX6 and KIF21A genes were amplified by
polymerase chain reaction (PCR) from genomic DNA.
Primers for all coding exons and exon-intron boundaries
of the target genes were designed by the Primer3 program
(http://frodo.wi.mit.edu/). All PCR primer sequences are
not shown but can be available on request. Amplifications
were carried out in 50 μL of standard PCR buffer
containing 1.5 mM MgCl2, 0.2 mM of each dNTP, 0.5 μM
of each primer, 1 U of Taq polymerase, and 50 ng of DNA.
The amplification program was an initial 2 min denatur-
ation at 98°C, followed by 30 cycles of 30 s at 94°C, 30 s
at 55°C, 1 min at 72°C, and a final 7 min extension step
at 72°C. The PCR products were extracted using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). DNA
sequencing analysis was performed using the BigDye Ter-
minator Cycle Sequencing V3.1 kit on an ABI PRISM 3130
Genetic Analyzer (Applied Biosystems). PCR products of
heterozygous mutants were ligated to pMD®18-T vectors
(Sagon, Shanghai, China), and subsequently sequenced
by the 3130 Genetic Analyzer. Sequencing results were
assembled and analyzed with the Seqman program of
DNASTAR software (DNASTAR Inc, Madison, WI).
The referred standard sequence of the PAX6 and KIF21A
genes are from the GenBank (NM_001173464 for KIF21A,
NM_000280 for PAX6). The cDNA numbering +1 cor-
responds to A in the ATG translation initiation codon
in the reference sequence. Mutation naming followed
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Results
Since the proband inherited the phenotype of CFEOM1
from his mother, his KIF21A gene was sequenced. After
all coding regions of KIF21A gene were sequenced,
a heterozygous c.2860C > T (p.Arg954Trp) mutation
was found in exon 21 of KIF21A gene (Figure 2). In
addition, the c.2860C > T (p.Arg954Trp) mutation was
also detected in all affected family members with CFEOM
(individual I:1, II:2, and II:3) but was absent in individual
I:2, II:1, and II:4, as well as in 100 unaffected Chinese
control individuals.
Sequencing of PAX6 showed a heterozygous 1-base
pair deletion (c.745delC, p.Leu249TyrfsX22) in exon11
in the proband and his father. This results in a frame-
shift change in PAX6 predicted to produce a truncated
protein with the initial 248 amino acids similar to the
wild type PAX6 protein and 22 additional aberrant amino
acids followed by a premature stop codon. Thus, the
truncated mutant PAX6 protein is missing the final
152 amino acids of wild type PAX6 protein (Figure 2).
This change was absent by sequencing in 100 Chinese
male normal controls.
Discussion
In this study, we report the clinical features of a 7 year
old male with both CFEOM1 and congenital aniridia.
He inherited the c.2860C > T (p.Arg954Trp) mutation in
KIF21A from his mother, who also had CFEOM1, and the
c.745delC (p.Leu249TyrfsX22) mutation in PAX6 from his
father who had congenital aniridia.
The KIF21A gene comprises 38 exons and encodes a
1674 amino acid protein. Structurally, the KIF21A pro-
tein includes an N-terminal motor domain, a coiled-
coil domain, and a C-terminal WD-40 repeat domain
[4]. Functionally, the KIF21A protein is responsible for
the transport of membranous organelles, protein com-
plexes, and mRNAs to specific destinations within the
cell in a microtubule-and ATP-dependent manner. These
are essential for normal morphogenesis and functioning of
the cell [5]. To date, 13 mutations in the KIF21A gene are
reported to be detected in the affected individuals with
CFEOM, of which 12 are missense mutations [4,6-9].
The c.2860C > T (p.Arg954Trp) missense mutation in
exon21 is the most common in the KIF21A gene and
accounts for 84% of KIF21A mutations seen in CFEOM
[4]. It has been detected in different ethnic populations,
including European, African, Arabian, and Asian [4]. R954
is located in the coiled-coil domain which comprises a
repeated heptad consensus sequences, and is regarded
as an important site for KIF21A function including
modulating the assembly and stability properties of theprotein structure and interaction. Three mutations at
Arg954 (p.Arg954Trp, Arg954Gln and Arg954Leu) [4] were
identified in the patients with CFEOM. The recurrent mu-
tation of p.Arg954Trp in our study further supports the
idea that R954 is a mutation “hotspot” in the KIF21A.
PAX6 is a member of the paired box gene family and
encodes a transcriptional regulator that recognizes target
genes through its highly conserved paired-box and
homeobox domains [10]. The human PAX6 gene consists
of 14 exons and may produce at least three transcript
isoforms by alternative splicing. The p.Leu249TyrfsX22
mutation in this study is located in the homeodomain and
caused by a 1-bp deletion which results in a frameshift
mutation and would be predicted to produce a truncated
protein with the initial 248 amino acids similar to the wild
type PAX6 protein followed by an additional 22 aberrant
amino acids and then a premature termination codon
(PTC). In mammalian cells, mRNAs containing a PTC
due to a nonsense mutation or a frameshift mutation in
an internal exon are usually recognized and degraded by
nonsense-mediated mRNA decay (NMD), which is a
preventive mechanism for eliminating the production of
potentially deleterious truncated proteins interfering with
normal cellular processes [11]. As a general rule, mamma-
lian transcripts that contain a PTC more than 50–55 nucle-
otides (nt) upstream of the last exon-exon junction will be
subjected to NMD, while PTCs located within 50–55 nt or
downstream of the last exon-exon junction are not recog-
nized by NMD and a truncated protein may be formed.
The p.Leu249TyrfsX22 mutation occurred in exon11 of the
PAX6 gene and produced a PTC 369 nucleotides distant
from last exon-exon junction, and would be predicted to be
recognized by the NMD mechanism.
Functionally, the PAX6 protein is critical for the de-
velopment of various tissues and organs, particularly
the eye and the nervous system. Mutations in the PAX6
gene may cause aniridia, coloboma, hereditary keratitis
(KERH, OMIM:148190), bilateral optic nerve hypoplasia
[12] (BONH), interhemispheric brain malformations
[3], Peters syndrome (PAN, OMIM 604229), Gillespie
syndrome (OMIM:206700), and probably myopia [13].
Mutations in the PAX6 have not yet been reported to be
associated with congenital fibrosis of extraocular muscle,
but may be associated with congenital ptosis [14].
The boy in this study has the clinical features of
CFEOM1 and congenital aniridia. By DNA sequence ana-
lysis, we found that he inherited the p.Arg954Trp mutation
in the KIF21A from his mother and the p.Leu249TyrfsX22
mutation from his father. Although PAX6 mutations may
cause the phenotype of congenital ptosis, comparing the
feature of ptosis with his mother, we didn’t find his bilateral
ptosis was more serious than his mother’s, which suggested
that his bilateral ptosis with ophthalmoplegia was caused
by the KIF21A mutation. As an offspring in the family with
A
Wild type
Mutant type c.2860C>T,  Arg954 Trp
B
1-bp deletion (c)
Figure 2 Heterozygous mutations in the KIF21A and PAX6. (A) A C to T change at 2860 nt in exon 21 of the KIF21A resulting in Arginine (A)
at condon 954 substituted by Tryptophan (W); (B) A 1-bp deletion in exon11 of PAX6 gene was detected by cloning sequencing, which resulted
in a frameshift mutation (p.Leu249TyrfsX22).
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an affected individual with either CFEOM1 or aniridia,
and would be 25% risk of developing both CFEOM1 andaniridia. The probability of developing both CFEOM1
and aniridia for their additional child would be 25%, should
his parents produce an additional child. However, since his
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PAX6 gene rather than a contiguous gene deletion includ-
ing WT1, neither he nor his offspring will be at increased
risk for the WAGR syndrome.
Conclusion
In summary, we identified a 7 year old male with aniridia
and congenital fibrosis of the extraocular muscles as a
result of independent mutations in the PAX6 and KIF21A
genes, inherited independently from his father and mother.
The c.2860C > T (p.Arg954Trp) from his mother is a
recurrent mutation in the KIF21A and the c.745delC
(p.Leu249TyrfsX22) mutation in the PAX6 from his
father is a novel mutation which expands the mutation
spectrum of PAX6.
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